Heart surgery drug shows promise in cutting lung complications

NCT ID NCT07237243

Completed Disease control Sponsor: Qin Zhang Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether giving ulinastatin during heart surgery can lower the chance of lung complications like infections or breathing failure. Researchers analyzed data from over 4,500 patients and also used computer models to understand how the drug works. The results suggest ulinastatin may help, but more research is needed to be sure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ulinastatin
What this could lead to: If successful, this could point toward a way to reduce serious lung problems after heart surgery, potentially improving recovery.
What could go wrong: This is a retrospective study, not a randomized trial, so results may be influenced by other factors. The findings need confirmation in larger, more rigorous studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC DISEASE REQUIRING ELECTIVE CARDIAC SURGERY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC SURGERY PULMONARY COMPLICATION

Contacts and locations

Locations

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.